Overview

  • Product nameK252a
  • Description
    Highly potent inhibitor of protein and CAM kinases
  • Biological descriptionHighly potent, cell-permeable inhibitor of protein kinases such as PKA, PKC, PKG (IC50 = 18-25 nM), Serine/threonine protein kinases (IC50 values are 10-20 nM) and CAM kinase II (Ki = 1.8 nM). Analog of staurosporine (ab120056), exhibits a wide range of effects including neuroprotection and improvement of psoriasis in vivo.
  • Purity> 99%

Properties

    Associated products

    References for K252a (ab120419)

    This product has been referenced in:
    • Pan J  et al. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways. Mol Pharmacol 72:1607-18 (2007). Read more (PubMed: 17855652) »
    • Raychaudhuri SP  et al. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol 122:812-9 (2004). Read more (PubMed: 15086569) »
    • Hashimoto Y  et al. Potent and preferential inhibition of Ca2+/calmodulin-dependent protein kinase II by K252a and its derivative, KT5926. Biochem Biophys Res Commun 181:423-9 (1991). Read more (PubMed: 1659814) »
    • Kase H  et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 142:436-40 (1987). Read more (PubMed: 3028414) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120419.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"